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Summary 
Immunoglobulin (Ig) A serves as the first line of humoral defense at all mucosal surfaces and is 
present in large quantities in blood. In playing its role in humoral immunity, lgA interacts with 
a variety of effector molecules present both in serum and on the surfaces  of immune and in- 
flammatory cells.  To study these interactions, we previously established expression of human 
IgA1  in insect cells using recombinant baculoviruses and showed that the expressed antibody is 
a structurally and functionally intact polypeptide useful for examining the molecular properties 
of IgA. Indeed, since the Cox2 N-linked glycosylation site lies near the Fab-distal pole of Ca2, 
the inability of a mutant IgA1  lacking Cot2 N-glycosylation to bind its cognate receptor sug- 
gested that the monocyte Fca receptor (mFcotR) recognizes IgA at a hinge-distal site encom- 
passing the boundary between the Cot2 and Cot3 domains. In this report, we utilize both do- 
main-swapped IgA/IgG and point-mutated IgA chimeras to verify the above hypothesis. Using 
an antigen-specific rosetting assay and a mFcotR-expressing cell line, we show that:  (a)  Cot2 
and Ca3 together are necessary and sufficient for binding;  (b) neither the IgA hinge nor the 
tailpiece is necessary for binding; (c) mutations away from the interdomain boundary do not af- 
fect binding; and (d) mutations located near the three-dimensional boundary between Cot2 and 
Ca3 completely disrupt binding. Taken together, these results localize the mFcaR recognition 
site on IgA to the boundary region between the second and third constant domains -- a site 
analogous to that recognized by Staphylococcus  aureus protein A on IgG. The use of this hinge- 
distal site is, to date, unique among Fc receptors of the Ig superfamily. 
I 
gA is the  dominant  Ig at mucosal surfaces  and in exo- 
crine secretions; thus,  in intact mammals,  this molecule 
serves as the first line of  immunologic defense against patho- 
genic invasion. Moreover, its high concentration in serum 
(1) and its ability to recruit neutrophils (2), eosinophils (3), 
and macrophages  (4)  suggest  a role in immune  responses 
against pathogens that have already penetrated mucosal bar- 
tiers. In fulfilling its functions, IgA participates in a variety 
of intermolecular associations including those with the in- 
tracellular folding/assembly apparatus, the C3Bb convertase 
of complement (5),  the poly-Ig receptor (plgR)  (6),  and 
the surface receptors of cells that respond to IgA-coated an- 
tigens. Each of these interactions depends on the ability of 
the relevant effector molecules to recognize specific and as 
yet undefined surfaces on the IgA constant region (Ca). To 
fully understand  and  to  potentially beneficially modulate 
immunity mediated by IgA,  the  specific features of these 
interactions should be investigated; in particular, the inter- 
action between IgA and CD89 is of interest.  CD89 is the 
monocyte/granulocyte Fcot receptor (mFcotR) 1 that serves 
to  trigger inflammatory cell responses  against  IgA-coated 
antigens  (2,  4).  It is  a  single-pass  transmembrane  protein 
possessing  two  Ig-type  extracellular domains.  The mole- 
cule  shows  similarity  to  the  high-affinity FceR  and  the 
three Fc~/R (CD 64, 32, and 16) but is more distantly re- 
lated to these receptors than they are to one another (7). 
Previously (8), recombinant bactdoviruses were shown to 
be useful for the expression of  antigen-specific, human lgA1 
whose  in  vitro  functional  and  immunologic  properties 
were largely identical to those of the natural protein. Using 
that system, it was also shown that mutant hapten-specific 
IgA lacking C~x2 N-linked glycosylation fails to mediate in- 
teraction between hapten-coated targets and cells express- 
ing  the  monocytic/granulocytic FcotR  CD89.  However, 
1Abbreviations used in this paper: ars, p-azophenylarsonate;  mFc~tR, mono- 
cyte/granulocyte  Fcc~ receptor;  Vars, V region ofhybridoma  93G7. 
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teraction even though its N-hnked sugars differ in compo- 
sition from those found in natural human  IgA. It was pos- 
tulated  that  the  sugar  per  se  does  not  participate  in  the 
interaction between Cot and its cognate receptor (since to a 
first approximation, sugar composition appeared irrelevant). 
Rather, it was hypothesized that the mere presence of Cot2 
glycosylation serves  to  maintain  a  functional  binding  site 
through  conformational  effects.  Based  on  the  location of 
the  sugar distal to  the  classical intradomain disulfide bond 
in Cot2, it was further hypothesized that the site on Cot rec- 
ognized by mFcotlk lay at  the  intradomain boundary be- 
tween Cot2 and Cot3 (8), and not at proximal Cot2 abutting 
the hinge as would be expected given the paradigm estab- 
lished in the C~/and C~ systems (9-12, and reviewed in 13). 
To  test the  above prediction, various  domain-swapped 
and point-mutated IgA1 molecules with hapten specificity 
were  expressed in insect cells and assayed for their ability 
to  mediate interaction between  hapten-coated targets and 
mFcotR.-expressing ceils. The  results of these assays aflSrm 
the hypothesis. 
Materials and Methods 
Synthesis of Coding Regions.  DNA fragments corresponding to 
the  heavy and  light  chain  V  regions  of the  hybridoma 93G7 
(Vars) were amplified using PCP,- from the previously described 
plasmids pH',/1-360E and pHK-360E  (14),  respectively; these V 
regions encode p-azophenylarsonate (ars) specificity. The  oligo- 
nucleotide primers for these amplifications included a  5'  Ncol 
site at the initiation codon and a 12-nucleotide antisense overlap 
with Cc~ at the 3' end. The coding regions of human Cod, C~/1, 
and CK were obtained from human peripheral blood leukocyte 
tLNA by reverse transcription-PCR as previously described (15). 
In this case,  the primers included a  12-nucleotide sense overlap 
with the appropriate V  region at the 5' end and an XbaI site at 
the  3'  end.  The  appropriate V  and  C  regions were joined by 
PCtL overlap extension (16) using a total overlap of 24 bp at the 
highest anneahng temperature that still yielded a product. A simi- 
lar approach was  used to  create domain-swapped mutants.  For 
example, to create a sequence with the Vars  and C~/1 domains 
coupled to Fcet, the 5' Vars primer was used along with a 3' C~1 
primer containing an overlap with Co~2 to amplify a 5' fragment; 
this was joined to  an analogously generated 3'  fragment (made 
using a 5' Cox2 primer with a C~1  overlap and the standard Cc~ 
3' primer) using overlap extension. Point mutants were generated 
using overlap primers that incorporate the point mutation, tLesi- 
due locations as described in the text are numbered according to 
Kabat et al.  (17).  All amphfications were performed using PFU 
polymerase (2.5U; Stratagene Inc., LaJolla, CA) in order to min- 
imize PCtL errors. 
Construction of Baculovirus Transfer Vectors.  The resultant inserts 
were digested, purified on low-melt agarose gels, and ligated into 
the  unique  NcoI  and  XbaI  sites  in  pH-360EX  using standard 
techniques  (18).  All constructs were  sequenced using T7  poly- 
merase (Sequenase;  United States Biochemical Corp., Cleveland, 
OH) or Taq polymerase (Fisher Biosciences, Pittsburgh, PA) us- 
ing the manufacturer's protocols. 
Production of Recombinant Viruses.  Transfer vector DNA was iso- 
lated by alkahne lysis "miniprep" except that DNA was also sub- 
jected to sequential protease K digestion, phenol/chloroform ex- 
traction, and chloroform extraction before final precipitation, all 
as described (18). 4 I~g of transfer plasmid was cotransfected with 
linear  wild-type baculoviral DNA  into  Spodoptera frugiperidum 
cells using cationic liposomes (Invitrogen, San Diego, CA) as in- 
structed by the manufacturer, except that 0.25  p,g of linear DNA 
was  used.  Growth,  plaque purification, and titration of viruses 
was standard (19). 
Isolation of Recombinant Proteins.  Cell supernatants  were adjusted 
to 20 mM Tris, pH 7.5,  10 mM EGTA, 10 mM EDTA, and 1 
mM PMSF. They were then centrifuged at 90,000 g for 40 rain. 
Resultant supernatant was then adjusted to 40%  saturation with 
ammonium sulfate  and left standing for more than 1 h  at 25~ 
the mixture was centrifuged at 2,500 g for 40 min at 25~  The 
pellets were  resuspended  in  Milli-Q water  and  reprecipitated. 
The final pellet was resuspended into PBS,  pH 7.4/0.02%  Na- 
azide and dialyzed into same. 
Protein Analysis.  Supernatants were  analyzed by SDS-PAGE 
according to Laemmli (20) with and without reduction. Imrnu- 
noblotting was performed in 10% methanol/10 mM sodium cy- 
clohexylamino-propanesulfonate (CAPS),  pH  11,  onto  polyvi- 
nyhdene  difluoride  membranes  (0.2  p~m, Millipore  Corp., 
Bedford,  MA).  Membranes were  blocked with  2%  nonfat  dry 
milk in TBST (20 mM Tris-C1, pH 7.5,  150  mM NaCI, 0.05% 
bovine albumin,  and 0.05%  Tween 20.  Proteins were detected 
using appropriate antisera conjugated to alkaline phosphatase fol- 
lowed by nitro-blue tetrazolium and bromochloroindole phos- 
phate (NBT-BCIP; GIBCO-BRL, Gaithersburg, MD) according 
to supphed instructions. 
ELISA-based Assays.  IgA concentrations were  measured us- 
ing sandwich ELISA. 200 ng of monoclonal anti-IgA1 antibody 
(courtesy of Roy Jefferis, University of Birmingham,  UK  [21]) 
was coated onto wells of Maxisorp (Nunc, [koskilde, Denmark) 
96-well plates that were then blocked using 200 rnl 2% nonfat dry 
milk in TBST (25~  for >2 h). Recombinant wild-type ars-spe- 
cific IgA1 or purified serum IgA1 standard was then diluted into 
100  ml TBST,  apphed to  the coated wells, and detected using 
goat anti-human IgA coupled to alkaline phosphatase (The Bind- 
ing Site Ltd., San Diego, CA). Plates were developed using p-nitro- 
phenyl phosphate (1  mg/ml in 50 mM  Tris, pH 9.5,  100  mM 
NaCI,  and  50  mM  MgC12). Recombinant  wild-type IgA was 
quantitated by comparison of sample absorbances to the standard 
dilution  curve.  Ars-specific mutant  antibody was  detected,  as- 
sayed  for  reactivity  with  mAbs,  and  quantitated  by  sandwich 
ELISA as above except that ars-derivatized BSA was used as the 
capture reagent and anti-human  CK  coupled to  alkaline phos- 
phatase (Sigma Chemical Co., St. Louis, MO) was used as the de- 
tecting reagent. Mutants were standardized by comparison to the 
previously quantitated wild-type recombinant IgA1. Standardized 
mutant and wild-type IgA1 molecules were also compared with 
regard to reactivity  with mAbs M4Cll (anti-Fab), M4D8 (anti-Fc), 
and 2D7 (anti-Fc requiring intact interchain association)  (21) using 
the technique described above with ars-BSA as the capture reagent. 
All steps were followed by three sequential washes with 200 I.d 
TBST. All coating steps were at room temperature for over 1 h. 
FcolR-expressing Cells.  The promyelocytic leukemia line HL- 
60  (22) was obtained from the American Type Culture Collec- 
tion (tLockville, MD) and propagated in SSFL medium. SSFL is a 
variant of a serum-free medium described by Baker and Knob- 
lock (23) and consists  of IMDM (Sigma Chemical Co.) reconsti- 
tuted as per manufacturer and supplemented with 30 mg/1 iron- 
saturated human transferrin (Boehringer Mannheim, Indianapolis, 
IN), 5 rag/1 porcine insuhn,  50 mg/l low-endotoxin bovine al- 
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suspension (all from Sigma Chemical Co.). Cells were induced to 
express mFcalk/CD89  by growth  in  SSFL with  500  nM  cal- 
citriol (courtesy of Milan Uskokovic  and  Hoffman-La Roche, 
Nutley, NJ) for 5 d as described (24). Induction of CD89 on HL- 
60 cells was checked by standard flow cytometry using the My43 
(IgM) anti-CD89 mAb (4). 
Rosetting.  Sheep E (Colorado Serum Co., Denver, CO) were 
derivatized with ars exactly as described (25) after which they were 
washed five times in 100  vol of HBSS. The haptenated E  (HE) 
were then coated with sensitizing antibody or random serum Ig 
(in HBSS) for 12 h at 4~  followed by further washing. 100  ~1 
of 1% antibody-coated HE (AHE) was then mixed with 2 ￿  105 
calcitriol-induced HL-60 cells,  also in 100  p~l of HBSS, with or 
without  inhibitors. The  mixture was  gently agitated and incu- 
bated on ice for 20 rain; the cells were then pelleted at 130g in a 
swinging bucket microfuge and left on ice for a further 2 h. Su- 
pematant was removed and the pellet was resuspended in 300 rnl 
HBSS containing 0.0025% acridine orange. The cells were then 
dribbled on a slide, covered with a coverslip, and counted under 
UV illumination and low visible light such that rosettes and HL-60 
nuclear fluorescence were simultaneously visible. 200 lymphocytes 
were counted and percent rosetting was expressed as percent ro- 
setted HL-60 cells/total HL-60 counted (mean of three experi- 
ments). Rosettes were defined as fluorescent cells attached to four 
or more AHE.  The  specificity of all results was verified by the 
ability of both My43 and excess nonspecific IgA1 to individually 
inhibit rosetting. 
Results 
Ce~2 and Ctz3 But Not the Hinge Are Necessar  g and Sufi- 
cientfor Binding.  In an  effort to  grossly localize the bind- 
ing site for mFcotlZk on Cot, mutant antibodies were gener- 
ated whose  C  regions were  composed of domains  of Cot 
and  Cy  in  all possible permutations  (Table  1).  With  the 
exception  of  the  NH2-terminal  boundary  of  Cot2,  the 
NH2-  and  COOH-terminal  boundaries  of domains  were 
determined by the 5' and 3' limits, respectively, of the cor- 
responding genomic exons. In the case of Cot2, two NH 2- 
terminal limits were  utilized, one  at the  beginning of the 
IgA1 hinge (the exonic 5' limit) and the other at the end of 
the IgA1 hinge (substituting instead the IgG1  hinge). This 
was  done  so that the role of the  IgA hinge was  explicitly 
tested. An IgA lacking the COOH-terminal "tail" was also 
produced.  A  model  of IgA monomer  structure  has  been 
proposed (26)  that postulates a disulfide bond between the 
tail and a site in Cot2. Given such a model, it was important 
to determine the necessity of the tail for receptor binding; 
since in reaching the Cot2 cysteine, the tail would necessar- 
ily span the  Cot2-Cot3 boundary.  Correct construction  of 
each  mutant  was  verified by  complete  sequencing  of the 
coding regions and by immunoblotting of chimeric mole- 
cules with appropriate anti-Cot and anti-Cy antisera (8, and 
data not shown).  Binding of mutants  to  FcotP,. was  tested 
using a previously described rosetting assay (4,  8) in which 
ars-derivatized E  coated with anti-ars mutants were exam- 
ined for their ability to rosette around HL-60 cells induced 
to express mFcotR (24).  In all cases, specificity of rosetting 
was verified by the ability of anti-mFcotK mAb (My43)  or 
a vast excess of soluble IgA to competitively inhibit rosetting. 
The stated hypothesis involves an FcotR binding site at 
the boundary of the second and third constant domains, in- 
cluding surface  provided  by  both  domains,  analogous  to 
the site on C~/recognized by the B  fragment of protein A 
(27, 28). This hypothesis predicted that, of the IgA/G mu- 
tants listed in Table  1,  only those with both Fcot domains 
present could have bound cognate receptor and thus medi- 
ated  specific  rosetting.  Furthermore,  the  removal  of the 
hinge (though genetically part of Cot2) should not have af- 
fected rosetting. No prediction was made regarding the tail 
first, because of the uncertainty regarding the existence of 
the tail-Cot2 disulfide, and second, because of the inability 
to predict whether the tail would actually block the postu- 
lated binding site were that disulfide to exist. The results of 
rosetting  experiments  utilizing the  domain-swapped  mu- 
tants  appear in the last column  of Table  1.  As predicted, 
only the VAAA and VGAA chimeras were able to mediate 
rosetting through mFcotR despite the latter molecule's lack 
of an IgA hinge; thus, both Cot2 and Cot3 are necessary and 
sufficient for binding to CD89 irrespective of the hinge re- 
gion. Removal of the tail failed to interfere with rosetting 
as demonstrated by the ability of the VAAA t-  antibody to 
mediate rosetting. 
This  interpretation of the  data is predicated on  the  as- 
sumption that individual Cot domains in the chimeras fold 
appropriately and somewhat independently despite substi- 
tution of  wild-type neighboring domains with analogues from 
C~/1.  It is believed, however, that this assumption is reli- 
Table 1.  Domain  Composition of Chimeric Constructs and Their 
Capacity to Mediate CD89-spedfic Rosetting 
Construct  C,1  Hinge  C~2  CH3  Tail  Binding** 
VAAA  ~x  ot  ot  ot  +  + + 
VAAG  ot  cx  et  ",/  n/a~  -  - 
VAGA  ot  oc  ~  ot  +  -  - 
VAGG  a  "y  ~  3'  n/a  -  - 
VGAA  ~  ',/  ot  ot  +  + + 
VGAG  ~  ot  ot  ,,/  n/a  -  - 
VGGA  ~  "y  ~  ~t  +  -  - 
VGGG  ~/  3'  ~  ~  n/a  -  - 
VAAA t-  ot  ~t  cx  ot  ++ 
Domain boundaries  are those of the genomic  exons except for con- 
struct VGAA which incorporates the hinge  of IgG1  rather  than  the 
IgAl hinge encoded by the C~2 exon oflgA1. 
* + +  refers to rosetting of >25% of assayed HL-60 cells taken as the 
average of three experiments; --  refers to rosetting of <5% of assayed 
HL-60 cells taken  as the average of three  experiments.  Root-mean- 
squared deviations of positive and negative results were no greater than 
10 and 50% of the means, respectively. 
*The specificity of all results was verified by the ability of anti-CD89 
mAb as well as vast excess of free, nonspecific IgA1 to block rosetting. 
~Not applicable since IgG has no terminal tail. 
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with  good  yield  as  disulfide-linked  C H dimers  (i.e.,  as  Ig 
monomers)  that are recognized  in solution  by appropriate 
polyclonal and monoclonal reagents (8, and data not shown). 
A priori, it is unlikely that grossly malfolded molecules would 
be secreted from the endoplasmic reticulum to form stable, 
nonaggregating  solutions.  Also,  the  presence  of interchain 
cystines and correct surface epitopes argues for, at the least, 
correct  orientation  of buried  and  exposed  surfaces  that 
likely constrain attainable backbone conformations to those 
close  to  wild  type.  Second,  the  robustness  of Ig domain 
folding is strongly supported  by the literature  which  dem- 
onstrates largely intact structure and/or function  of mutant 
Igs in the face of (a) domain chimerism (28-30),  (b) neigh- 
boring domain removal (27), and (c) unnatural linkages be- 
tween domains (31). Lastly, the above data demonstrate the 
ability of Fco~ to, at the very least, maintain receptor-bind- 
ing conformation in spite of sequence  changes at the NH 2 
and  COOH  termini  (e.g.,  deletion  of the tail,  substitution 
of the  hinge  and/or  Cctl).  Nevertheless,  the  above  does 
not exclude the possibility that the CD89 binding site only 
requires  one  of the  Fc  domains,  with  the  other  domain 
merely stabilizing overall conformation. 
Mutation of Residues Predicted to Lie at the Cce2-Ccr  Bound- 
ary,  But Not Elsewhere,  Abrogate  IgA-mediated Rosetting.  To 
more finely probe the binding  site, point mutants  of IgA1 
were generated and assayed. Understanding  of the rationale 
behind these mutations is aided by referral to Fig.  1. Fig.  1 
shows an alignment of the sequences of Co~2 and Col3 ver- 
sus C3~2 and Cy3, respectively; secondary and tertiary struc- 
tural characteristics of the two C~/domains are indicated by 
symbols as explained in  the  figure legend  and  are  derived 
from the  data presented  by Deisenhofer  et al.  (27,  28).  As 
can be seen,  sequence  identity between  the  two  CH2  do- 
mains  (25%)  is much less than  that between  the  two  CH3 
domains  (40%);  thus,  prediction  of Co~2 structure  by anal- 
ogy to C~/2 is a risky endeavor. Fortunately however, much 
of the  area  of interest  lies  either  in  Cot3  or in  an  area  of 
CIx2  near  conserved  landmarks  (e.g.,  domain  boundaries, 
classical  cysteine,  strand-breaking  prolines)  that  allow  ori- 
entation.  Specifically,  the  classical  Ig  cysteine  at  position 
274 in Cot2 must he in an "upgoing"  13-strand as it does in 
all  Ig domains  (except,  of course,  those  lacking  the  cys- 
teine).  Thus,  the  previously  described  N271Q  mutation, 
which abrogated receptor binding, removed a carbohydrate 
chain from the NH2-terminal  (distal)  end of the ascending 
strand containing the classical cysteine.  By analogy to IgG, 
it had been predicted that a long loop located at the three- 
dimensional  interdomain  boundary  preceded  that  strand; 
tack  of the  carbohydrate  had  presumably  prevented  the 
loop from attaining its wild-type, receptor-binding confor- 
mation.  To  directly  test  the  role  of the  loop  in  receptor 
recognition,  L266  was  mutated  to  arginine.  This  site  was 
selected because it lies in a hydrophobic  stretch of residues 
whose  analogue  in  C"/  interacts  with  Staphylococcus  aureus 
protein A  (SPA)  (28, and Fig.  1). Furthemlore,  I266 in IgG 
is fully solvent exposed, is completely buried by protein A, 
and  does  not  participate  in  interactions  with  C'y3.  Muta- 
tion to arginine was chosen because such a change was ex- 
treme in terms of charge, hydrophobicity, and in particular, 
A  (247)  ~HO  (267)  (283) 
260v  270v|  280v  290v  300v 
HCA2  CCHPRLSLHRP-ALEDLLLGSEANLTCTLTGL-RDASGVTFTW--TPSSGKSAVQGP 
P.:  L  .P  :  :.L:::..:::TC.:.::  ::.:.V.F.W  .  .:A  P 
HCG2  APELLGGPSVFLFPPKPKD~SRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKT'~ 
250  ^  ~  260  ^  270  ^  ~  280  ^  288  ^  ~  300  ^ 
(301)  (321) 
310v  320v  330v  340v  350v 
HCA2  PERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKS 
.E  :  :  Y.V  SVL.  : W  :GK.:.C..:  .  :P:.  T:SK: 
HCG2  REEQYNSTYRWSVLTX~DWLNGKEYKCKVSNKALPAPIEKTISKAK 






(349)  (367)  (384} 
370v  380v  390v  400v  410V  420v 
GNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQ 
G:.  P:V.  LPP:,:EL:  N:  V:LTCL.:GF  P.D:  V  W  .S:.  P  ::Y  T  :: 
GQPREPQVYTLPPSRDELTKNQ-VSLTCLVKGFYPSDIAVEW--ESNGQPENNYKTTPPVL 
370  ^  381  ^  390  ^~  400  ^  ~  410  ^  420  ^ 
(401)  (419)  (439) 
430v  440v  450v  460v  470v 
EPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGK 
:  S:G  :F  :  S  L  V.  . W::G:.FSC  V  HEAL.  :T~K::.  :GK 
D-SDG--SFFLYSKLTVDKSRWQQGNVFSCSVMH~QKSLSLSPGK 
430  ^  440  ^  ~  450  ^  ~  460  ^  470  ^ 
B  346  280 
266 ~~~ 
465  "~ 
Figure 1.  (A) Alignment of the Fc domains of human lgA1 and IgG1. Letters between the two sequences signify identities; (:) one-nucleotide differ- 
ences in the respective codons; (- -) gaps. (CHO) N-linked carbohydrate positions; (bars) approximate 13-strand locations in the IgG sequence; and (boxes) 
residues in Fc~/known to interact with the B fral~nent of protein A (26, 27). The directionality of the {3-strands in three dimensions is indicated by ar- 
rows. (1") Strands that ascend toward the hinge; (,l,) strands that start more proximally and stretch away from the hinge. Primary numbering is according 
to Kabat et al. (17) with corresponding Eu residue numbering in parentheses. Alignments were performed using the DNASTAR  TM software (DNA- 
STALL, Madison, WI). (B) Ribbon drawing of the backbone of Fc3' based on the coordinates ofDeisenhofer et aL (27). Positions of Fcct mutations de- 
scribed in the text are numbered and positioned by analogy to FcT. Predicted positions of the Cot2 N-linked sugar are marked by the boxes. Coordinates 
were downloaded from the Brookhaven database and rendered using HyperChem  TM  software (Hypercube Inc., Waterloo, ON, Canada). 
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Boundary of a distal loop and 
ascending strand of C.2 domain 
Solvent-exposed residue of loop 
influenced by 271 N-linked sugar 
Proximal loop of C.3 that 
contacts the L266 loop 
Distal loop of C,2; not part of the 
C.2-CH  3 boundary 
Proximal loop of CH2 near the 
hinge 
Proximal loop of C.2 near the 
hinge and distinct  from that of R280 
Solvent-exposed distal loop 






*The letters preceding the numbers refer to wild-type residues; those following the numbers refer to the mutated residues; the numbers themselves 
refer to the position of the first mutated residue following the numbering scheme of Kabat et al. (17) with Eu numbering in parentheses. For exam- 
ple, ESK346KLE means that residues 346, 347, and 348 were mutated from ESK to KLE. Kabat numbering is used in the text. 
Here, distal and proximal refer to the position of a loop in three-dimensional space relative to the V region. 
+ +  refers to rosetting of >25% of assayed HL60 cells taken as the average of three experiments; --  refers to rosetting of <5% of assayed HL60 
cells taken as the average of three experiments, tLMS deviations of positive and negative results were no greater than 10 and 50% of the means, re- 
spectively. 
liThe specificity of all results was verified by the ability of anti-CD89 mAb as well as vast excess of free, nonspecific IgA1 to block rosetting. 
size. Since the rosetting assay is insensitive to changes in af- 
finity because of its multivalent nature  (data not shown), a 
mutation had to be selected that would disrupt the binding 
surface sufficiently to cause the great drop in affinity neces- 
sary for detection by rosetting.  As shown in Table  2,  the 
L266R mutation abrogates binding as predicted.  Since the 
domain-swapping  experiments  suggested  a  binding  site 
composed of surfaces from both CoL2 and Co~3, an L465R. 
mutant was also generated. This site, also by analogy to lgG, 
is predicted to lie in a  CoL3 loop in contact with the Co~2 
loop mutated above (see Fig.  1 B).  Furthermore,  N465  in 
IgG is solvent exposed, does not participate in interdomain 
contact, but does form part of the binding site for protein A 
(28). As shown in Table 2, the L465R mutation also abro- 
gates  binding  to  CD89.  Mutations  were  also  made  at 
hinge-proximal locations; none of these influences binding 
as assessed by rosetting. The E330R mutation fails to inter- 
fere with rosetting despite  its  predicted location in a loop 
near that of L266 and despite the partial interaction of IgG 
Q330 with protein A. 
In summary, mutations were made at positions predicted 
to lie  in five loop  regions  of the  Cc~2  domain.  Of these, 
only the mutation L2661<, in the loop between the 4-1 and 
4-2 strands (nomenclature ofEdmundson et al.  [32]), abro- 
gates  rosetting  mediated  by  Fcot-FcodL interaction.  Fur- 
thermore,  a C0t3 mutation  (L4651q.)  in the loop predicted 
to contact the region ofL266 also abrogates rosetting. 
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Discussion  of Results.  The results presented above are as 
follows.  (a)  Cox2 and  Co~3 are necessary and sufficient for 
binding of IgA to the mFcodL. Neither the Fab, the hinge, 
nor the tail appears to play a role in the interaction.  (b) The 
N271Q  mutation,  which  prevents  glycosylation in  Ce~2, 
eliminates interaction between Fccx and CD89.  (c) Of sev- 
eral mutations generated in the CoL2 interstrand loops, only 
a  mutation  (L2661L)  in  the  loop  that  bridges  strands  4-1 
and 4-2 abrogates mFccdK-mediated rosetting; by analogy 
to C~/, this loop likely lies at the Co~2-Cot3 interface.  (d) A 
mutation  (L465R) in a proximal loop of C~x3 predicted to 
contact the region of L266 at the Co~2-Cot3 boundary also 
abrogates rosetting. Several caveats to these results come to 
mind; these are addressed as follows. 
First,  positional analogy to IgG may be flawed, resulting 
in uninterpretable placement of mutations; this is highly un- 
likely.  The  conserved features  of the  Ig domain  and  this 
motif's robustness to sequence alteration are amply described 
(33).  Though there  is  no  doubt  that  the  details  (e.g.,  the 
residues at which strands  give way to loops, torsion angles 
of bonds,  etc.)  of IgA structure  differ from those  of IgG, 
the fundamental secondary structural assumptions employed 
in  this  study  are  likely valid,  especially in  C.3  where  se- 
quence identity between IgA and IgG is high, and at loca- 
tions in Cot2 close to well-conserved landmarks.  For exam- 
ple,  L266 appears before  the  first  classical cysteine  (which must lie in upgoing strand 4-2); since L266 also follows a 
conserved proline  (P259)  that  breaks  the  preceding  and 
downgoing 4-1 strand, the position in question must lie in 
a loop between strands  4-1 and 4-2 at the lower end of the 
domain. The fact that L266 is also part of a well-conserved 
hydrophobic region in  that loop  (28)  supports  the  argu- 
ment. Similar logic can be applied to the other mutant sites 
described earlier. A second caveat can be raised stating that 
the  above mutations  do  not  represent precise changes  in 
the binding site but rather gross distortions of domain con- 
formation that necessarily abrogate receptor binding by vir- 
tue of their global nature. This also is improbable on a pri- 
ori grounds alone since none of the mutations violate the 
[3-sandwich core of the domains. The Cot2 domain would 
seem to be particularly difficult to deform since its  back- 
bone is constrained not only by the conserved cysteine, but 
also by an additional interdomain cystine (residue 251) and 
at least one "extra" intradomain disulfide bond. Two em- 
pirical arguments against  this "global deformation" concern 
can also be made. First, the mutations that do not eliminate 
rosetting (especially the extensive SSGKS to VEGHT alter- 
ation  at postion 295)  serve as  an internal control for the 
method  since  they  fail  to  globally  distort  Fcot. Second, 
three anti-Cot mABs (M4Cll, M4D8, and 2D7) (21) react 
similarly with wild-type, L2661L,  and L465R IgA1  mole- 
cules, indicating that structural distortion induced by these 
mutations fails to extend to the epitopes probed by these 
mAbs,  and thus further arguing against  global destruction 
of Cot conformation by these alterations. 
Evolutionary Perspective.  Taken in toto, therefore, the re- 
stilts presented here indicate that CD89 recognizes IgA at a 
site at the boundary between the two Fc domains. Such a 
site is analogous to that on IgG recognized by SpA (27), the 
neonatal rodent intestinal Fc~/R FcR_n (34),  and an as yet 
unidentified factor involved in IgG clearance (35).  Except 
for the ot3 domain of  the MHC class I-like FcRn (36), nei- 
ther of the above characterized molecules belongs to the Ig 
superfamily (IgSF),  and none of the  above is involved in 
antibody effector function. CD89 is the first IgSF FcR whose 
binding site lies at a hinge-distal position; Fc~/R  I, II, and 
III (CD 64, 32, and 16, respectively), along with Fcd~I, all 
recognize their cognate Fc at positions on the penultimate 
Fc  domain just  distal  to and perhaps including the  hinge 
(9-12,  30).  This  divergence in  binding site  is  somewhat 
surprising  on  evolutionary  grounds.  Based  on  sequence 
analysis (7) and chromosomal location (37),  CD89 is more 
distantly related to the other four IgSF FcR than they are 
to  one  another;  nevertheless,  they are  related  and  likely 
evolved from a common ancestor. Simultaneously as these 
receptors diverged,  they  coevolved with  their  respective 
cognate Fc isotypic ligands,  which similarly arose by dupli- 
cation and adaptation from a common --  likely four do- 
main,  p~-like (38 and references therein) --  ancestral gene 
(39). If it is assumed that the primordial FcR recognized its 
respective primordial Fc at a site near the hinge, the CD89 
protein must have undergone a quantum change in speci- 
ficity from the primordial site to the present-day C.2-C~3 
boundary site.  Of course, the converse scenario where the 
primordial site was actually the  C~2-C,3 boundary is also 
possible.  Either way, an ancestral FcR probably had its Fc 
specificity suddenly  translocated,  but  not  eliminated,  by 
reasonably small  changes in sequence in the receptor itself 
and/or in  the  Fc  region;  however,  further comparative/ 
veterinary studies are necessary to shed light on this issue. 
The teleologic consequences of this difference in site lo- 
calization are perhaps more clear. The mucosal surfaces,  es- 
pecially those of the alimentary tract, are rich in nonspecific 
proteases (which are well known to cleave Igs at the hinge) 
as well as bacterial proteases whose only known substrate is 
human, gorilla, and chimpanzee IgA1  hinge  (reviewed in 
40-43). Heavy O-linked glycosylation of  the IgA-extended 
hinge presumably serves as sufficient protection against  at- 
tack by nonspecific proteases that evolve independently of 
IgA cleavage. In contrast to this relatively static relationship 
between IgA and host digestive enzymes, IgA of higher pri- 
mates and bacterial IgA proteases are locked in an ongoing 
process of"evolutionary one-upmanship." The wide prev- 
alence oflgA proteases in both gram-negative and -positive 
pathogenic bacteria, the lack of IgA protease in nonpatho- 
genic strains,  and  the  convergent functional evolution of 
unrelated IgA proteases, all demonstrate the adaptive bene- 
fit ofIgA protease to bacteria that colonize hominoids. Re- 
tention  (44)  of the  protease-resistant  (45),  hinge-deleted 
IgA2 isotype in hominoids whose IgA1  molecules are sus- 
ceptible to the bacterial IgA proteases represents the host 
side of  this coevolutionary process, the immediacy of  which 
is  further highlighted  by the  relatively recent appearance 
(based  on isoallotypic studies  of primate  IgA  [46])  of the 
A2m(2) allotype which resists cleavage by Clostridium  ramo- 
sum  IgA protease, the only IgA protease known to cleave 
IgA2m(1) (47).  Accordingly, because of the selective pres- 
sure of  pathogen proteases, IgA hinge variants prove advan- 
tageous to the host species.  Given the apparent ability of 
hinge  deletions  to  interfere  with  hinge-proximal  FcR 
binding sites  (9,  48),  the location of the phagocyte FcotR 
binding site away from the hinge may thus allow the reten- 
tion of resistant IgA hinge mutants  that nevertheless pre- 
serve the ability to recruit effector cells. 
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